Furthermore, it is worth highlighting that, at baseline, over 25% of our entire cohort were using an incretin medication, and 20% were using an SGLT-2 inhibitor, with high medication adherence (80% or better) self-reported by 77% of the subjects, and still met our inclusion criterion of an A1c 7.5% or higher (see Digital Supplement 2), illustrating the difficulty PwT2D have in managing diabetes and/or weight, despite their access to these newer, effective, and relatively costly medications. This evidence concerns the gene SLC5A2 and diabetes mellitus.